Please assess the completion status of the following clinical trial:

Trial Title: Raloxifene for Prevention of Bone Loss in Postmenopausal Patients Receiving Chronic Corticosteroid Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Postmenopausal patients with various chronic rheumatic diseases receiving chronic steroid therapy.~2. Stable disease for at least 6 months prior to study with a stable dose of steroid (prednisone \<= 10 mg/day or equivalent).~3. Baseline bone mineral density (BMD) of the lumbar spine T score \< -1.0.~Exclusion Criteria:~1. Patients with a history of thromboembolism.~2. Patients with positive antiphospholipid antibodies.~3. History of allergic reactions or intolerance to raloxifene or other SERMs.~4. Patients receiving bisphosphonates, parathyroid hormone, SERMs, anticonvulsants or anti-cytokine therapies within 6 months prior to study entry.~5. Patients with known bone disorders such as osteomalacia, renal osteodystrophy, and hyperparathyroidism.~6. Patients with abnormal uterine bleeding of unknown etiology.~7. Patients with serum creatinine level of \>= 200 umol/L.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): raloxifene
- 2 (Type: PLACEBO_COMPARATOR): placebo arm

Based on this trial design, predict the completion outcome and termination type (if applicable).